Subtype
Urinary Tract Neoplasm
CI-CAN-00001627Explore in graph →
Non-malignant558 active trials14 approved drugs29 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001627Explore in graph →
Clinical trials
2,187 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04314245 | Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for the Detection of Urothelial Carcinoma | completed | — | 1,170 | AnchorDx Medical Co., Ltd.INDUSTRY | 1 | May 24, 2023 | clinicaltrials |
| NCT03359239 | Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer | completed | Phase 1 | 10 | Matthew GalskyOTHER | 1 | May 16, 2023 | clinicaltrials |
| NCT03801954 | Implementation of Nutrition Education Videos for Patients Undergoing Radical Cystectomy | completed | — | 15 | University of Kansas Medical CenterOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT02043665 | CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)(STORM) | completed | Phase 1 | 85 | ViralyticsINDUSTRY | 3 | May 6, 2023 | clinicaltrials |
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | completed | Phase 1 | 37 | Fate TherapeuticsINDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT05540847 | Comparison of Interfascial Injection Versus Subpectineal Injection on Ultrasound-guided Obturator Nerve Block | completed | N/A | 60 | Diskapi Teaching and Research HospitalOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT02695771 | The Bladder Instillation Comparison Study(BIC) | completed | Phase 3 | 101 | Corewell Health WestOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT03758781 | IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors | completed | Phase 1 | 12 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT02371447 | VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer | completed | Phase 1 / Phase 2 | 39 | Swiss Cancer InstituteOTHER | 2 | Apr 13, 2023 | clinicaltrials |
| NCT03472274 | Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)(DUTRENEO) | completed | Phase 2 | 101 | Fundacion CRIS de Investigación para Vencer el CáncerOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT04487457 | Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy(CINECI) | completed | — | 31 | University Hospital, ToursOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT05799456 | Glycosaminoglycan Scores as Early Detection Biomarkers in Bladder Urothelial Carcinoma | completed | — | 106 | Jens NielsenOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT04209192 | Antimicrobial Prophylaxis in Patients Who Underwent a Transurethral Resection of Bladder (TURB) | completed | Phase 2 | 75 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05324033 | Sensitivity of Multiparametric MRI in Differentiation Between Muscle Invasive and Non-muscle Invasive Urinary Bladder Cancer | completed | — | 30 | Helwan UniversityOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03785925 | A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer(PIVOT-10) | completed | Phase 2 | 192 | Nektar TherapeuticsINDUSTRY | 18 | Mar 28, 2023 | clinicaltrials |
| NCT03775850 | A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | completed | Phase 1 | 69 | Evelo Biosciences, Inc.INDUSTRY | 2 | Mar 24, 2023 | clinicaltrials |
| NCT03718754 | En-bloc vs Conventional Resection of Primary Bladder Tumor(eBLOC) | completed | Phase 3 | 384 | David D'AndreaOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors(PIVOT-02) | completed | Phase 1 / Phase 2 | 557 | Nektar TherapeuticsINDUSTRY | 8 | Mar 13, 2023 | clinicaltrials |
| NCT03330886 | A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina | completed | — | 13 | Hoffmann-La RocheINDUSTRY | 1 | Mar 13, 2023 | clinicaltrials |
| NCT03854721 | A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer | completed | Phase 1 | 6 | Vaxiion TherapeuticsINDUSTRY | 1 | Mar 3, 2023 | clinicaltrials |
| NCT03689192 | Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors | completed | Phase 1 | 13 | Herlev HospitalOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT02217891 | IFACT: Incidental Findings in Advanced Cancer Therapy(IFACT) | completed | — | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT02281383 | Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer | completed | Phase 2 | 80 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT03058757 | The Effectiveness and Safety of Neoadjuvant Intravesical Mitomycin-C Instillation | completed | Phase 2 | 71 | National Cancer Center, KoreaOTHER_GOV | 1 | Jan 31, 2023 | clinicaltrials |
| NCT03212651 | Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab(PANDORE) | completed | Phase 2 | 41 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT03434132 | Open Versus Robot Assisted Radical Cystectomy With Totally Intracorporeal Urinary Diversion. | completed | N/A | 116 | Regina Elena Cancer InstituteOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT04430842 | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | completed | Phase 1 | 15 | Quadriga Biosciences, Inc.INDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
| NCT03617913 | Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer | completed | Phase 2 | 2 | Mayo ClinicOTHER | 1 | Jan 6, 2023 | clinicaltrials |
| NCT03307200 | Unmet Supportive Care Needs in Bladder Cancer Patients Undergoing Radical Cystectomy | completed | — | 90 | University Hospital, GhentOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT04598724 | Addressing Barriers to Palliative Care Use in Bladder Cancer | completed | — | 54 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 3, 2023 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT03464734 | Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma | completed | Phase 2 | 70 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT00805129 | Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium | completed | Phase 2 | 46 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT03980041 | Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) | completed | Phase 2 | 49 | Infinity Pharmaceuticals, Inc.INDUSTRY | 7 | Nov 25, 2022 | clinicaltrials |
| NCT03066310 | Urine-DNA Biomarkers in Detecting Bladder Cancer | completed | — | 125 | Xiangya Hospital of Central South UniversityOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT03325231 | Factors Influencing Patient Choice of Bladder Reconstruction Following Radical Cystectomy | completed | — | 140 | Swansea UniversityOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT03584659 | Patient-reported Outcomes in Bladder Cancer(iBLAD) | completed | N/A | 230 | Rigshospitalet, DenmarkOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT01688999 | Cabozantinib for Advanced Urothelial Cancer | completed | Phase 2 | 69 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2022 | clinicaltrials |
| NCT02437370 | Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer | completed | Phase 1 | 32 | University of California, DavisOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT02811952 | Measuring Urinary Nano Particles and Metallic Compounds in TCC Patients | completed | — | 100 | Carmel Medical CenterOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT00199849 | NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine | completed | Phase 1 | 18 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT00188695 | Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide | completed | Phase 1 / Phase 2 | 61 | University Health Network, TorontoOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT01869413 | Tranexamic Acid During Cystectomy Trial (TACT)(TACT) | completed | Phase 2 / Phase 3 | 354 | Ottawa Hospital Research InstituteOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT02500121 | Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer | completed | Phase 2 | 108 | Matthew GalskyOTHER | 1 | Sep 30, 2022 | clinicaltrials |
| NCT03505112 | The Effect of Goal-directed Hemodynamic Therapy in Radical Cystectomy | completed | N/A | 82 | Seoul National University HospitalOTHER | 1 | Sep 23, 2022 | clinicaltrials |
| NCT03558503 | A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer(OPTIMA II) | completed | Phase 2 | 63 | UroGen Pharma Ltd.INDUSTRY | 2 | Sep 16, 2022 | clinicaltrials |
| NCT03773666 | A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2) | completed | Phase 1 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT04077359 | Prospective Trial for Examining Hematuria Using Computed Tomography(PROTEHCT) | completed | N/A | 300 | Oslo University HospitalOTHER | 1 | Sep 6, 2022 | clinicaltrials |
Data updated 23 days agoSource updated May 24, 2023source: clinicaltrials